BeOne Medicines (ONC) Cash & Current Investments (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Cash & Current Investments data on file, last reported at $4.8 billion in Q1 2026.

• Quarterly Cash & Current Investments rose 90.42% year-over-year to $4.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 90.42% YoY) and the FY2025 annual result came in at $4.5 billion, up 73.08% from the prior year.
• Cash & Current Investments climbed to $4.8 billion in Q1 2026 per ONC's latest filing, from $4.5 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $5.7 billion in Q2 2022 and bottomed at $872.2 million in Q3 2022.
• The 5-year median for Cash & Current Investments is $3.2 billion (2023), against an average of $3.3 billion.
• The widest annual swing landed in 2022, when Cash & Current Investments sank 77.73%; it then soared 263.95% in 2023.
• Tracing ONC's Cash & Current Investments over 5 years: stood at $4.5 billion in 2022, then declined by 30.0% to $3.2 billion in 2023, then slipped by 17.23% to $2.6 billion in 2024, then surged by 73.08% to $4.5 billion in 2025, then rose by 5.37% to $4.8 billion in 2026.
• Per Business Quant, the three latest ONC Cash & Current Investments figures stand at $4.8 billion (Q1 2026), $4.5 billion (Q4 2025), and $4.0 billion (Q3 2025).

Peer Comparison